Mass vaccination campaigns for polio eradication: An essential strategy for success

Current Topics in Microbiology and Immunology

Volumn 304, Issue , 2006, Pages 195-220

  Sutter, R W ^a   Maher, C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

DISEASE CONTROL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; ENTEROVIRUS; ERADICATION THERAPY; HUMAN; IMMUNOGENICITY; MASS IMMUNIZATION; PARALYSIS; POLIOMYELITIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; DISEASE TRANSMISSION; HEALTH CARE PLANNING; HEALTH SURVEY; IMMUNOLOGY; QUALITY CONTROL;

ENTEROVIRUS; POLIOVIRUS;

COMMUNITY HEALTH PLANNING; HUMANS; MASS IMMUNIZATION; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; POPULATION SURVEILLANCE; QUALITY CONTROL;

EID: 34548682762     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-540-36583-4_11     Document Type: Review

References (71)

1. Sutter RW, Kew OM, Cochi SL (2003) Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA (eds), 4th edn. Vaccines. W.B. Saunders Company, Philadelphia, 25:651-705.
2. Majiyagbe J (2004) The volunteers' contribution to polio eradication. Bull WHO 82:2
3. World Health Assembly (1988) Polio eradication by the year 2000. Resolutions of the 41th World Health Assembly. Geneva: World Health Organization, 1988 (WHA resolution no. 41.28)
4. Hull H, Ward NA, Hull B, Milstien JB, de Quadros C (1994) Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343:1331-1337
5. Smith J (1990) Patenting the Sun. Polio and the Salk Vaccine. William Morrow & Company, New York
6. Chumakov MP, Voroshilova MK, Drozdov SG, et al. (1961) Some results of the work on mass immunization in the Soviet Union with live poliovirus vaccine prepared from Sabin strains. Bull WHO 25:79-91
7. Agol VI, Drozdov SG (1993) Russian contribution to OPV. Biologicals 21:321-325
8. Sabin AB (1985) Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 151:420-436
9. Sabin AB (1984) Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis 6(Suppl 2):S391-S396
10. Robertson HE, Acker MS, Dillenberg HO, et al. (1962) Community-wide use of a "balanced" trivalent oral poliovirus vaccine (Sabin): a report of the 1961 trial at Prince Albert, Saskatchewan. Can Public Health J 53:179-191
11. CDC. Poliomyelitis Prevention in the United States (1997) Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 46(RR-3)
12. CDC (2000) Poliomyelitis Prevention in the United States. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 49(RR-5)
13. Ofusu-Amahh S, Kratzer JH, Nicholas DD (1977) Is poliomyelitis a serious problem in developing countries? - lameness in Ghanaian schools. Brit Med J i:1012-1014
14. Bernier RH (1984) Some observations on poliomyelitis lameness surveys. Rev Infect Dis 6(Suppl.2):S371-S375
15. Cruz RR (1984) Cuba: mass polio vaccination program, 1962-1982. Rev Infect Dis 6(Suppl.2):S408-S412
16. Mas Lago P, Ramon Bravo J, Andrus JK, Comellas MM, Galindo MA, de Quadros CA, Bell E (1994) Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. Bull WHO 72:221-225
17. Mas Lago P (1999) Eradication of poliomyelitis in Cuba: a historical perspective. Bull WHO 77:681-687
18. Henderson RH (1984) The Expanded Programme on Immunization of the World Health Organization. Rev Infect Dis 6(Suppl.2):S475-S479
19. Grant JP (1991) Reaching the unreached: a miracle in the making. Asia Pac J Public Health 5:154-162
20. Murray C, Kreuser J, Whang W (1994) Cost-effectiveness analysis and policy choices: investing in health systems. Bull WHO 72:663-674
21. Vaccine and Biologicals Department (2003) WHO vaccine-preventable diseases: Monitoring system. 2003 global summary. Geneva: World Health Organization, (WHO/V&B/03.20)
22. McBean AM, Thoms ML, Albrecht P, et al. (1988) Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccine. Am J Epidemiol 128:615-628
23. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990). Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 162:1291-1297
24. Patriarca PA, Wright PF, John TJ (1991) Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 13:926-939
25. Domök I, Balayan MS, Fayinka OA, Skrtic N, Soneji AD, Harland PS (1974) Factors affecting the efficacy of live poliovirus vaccine in warm climates. Efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda. Bull WHO 51:333-347
26. Expanded Program on Immunization (1989) Global Advisory Group (1988). Wkly Epidemiol Rec 64:5-10
27. Rezapkin GV, Norwood LP, Taffs RE, et al. (1995) Microevaluation of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control. Virology 211:377-384
28. Nathanson N, Horn SD (1992) Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988. Vaccine 10:469-474
29. Patriarca PA, Laender F, Palmeira G, et al. (1988) Randomized trial of alternative formulations of orla poliovaccine in Brazil. Lancet i:429-433
30. Patriarca PA, Linkins RW, Sutter RW, Orenstein WA (1993) Optimal schedule for the administration of oral poliovirus vaccine. In Kurstak E (ed). Measles and poliomyelitis - vaccines and immunization. Springer, New York, Chapter 24 pp 303-313
31. Milstien JB, Lemon SM, Wright PF (1997) Development of a more thermostable poliovirus vaccine. J Infect Dis 175(Suppl.1):S247-S253
32. Anonymous (1996) Vaccine vial monitors take guesswork out of immunization. Vaccine Immun News 1:7-8
33. Heymann DL, Murphy K, Brigaud M, et al. (1987) Oral poliovirus vaccine in tropical Africa: greater impact on incidence of paralytic disease than expected from coverage surveys and seroconversion rates. Bull WHO 65:495-501
34. Olivé J-M, Risi JB Jr, de Quadros CA (1977) National immunization days: Experience in Latin America. J Infect Dis 175(Suppl.1):S189-S193
35. Bilous J, Maher C, Tangermann RH, Aylward RB, et al. (1997) The experience of countries in the Western Pacific Region in conducting national immunization days for polio eradication. J Infect Dis 175(Suppl.1):S194-S197
36. Tangermann RH; Hull HF, Jafari H, Nkowane B, Everts H, Aylward BR (2000) Eradication of poliomyelitis in countries affected by conflict. Bull WHO 78:330-338
37. CDC (1999) Progress toward poliomyelitis eradication during armed conflict - Somalia and Southern Sudan, January 1998-June 1999. MMWR Morb Mortal Wkly Rep 48:633-637
38. Benyesh-Melnick M, Melnick JL, Rawls WE, et al. (1967) Studies on the immongenicity, communicability, and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 86:112-136
39. Risi JB (1984) The control of poliomyelitis in Brazil. Rev Infect Dis 6(Suppl 2):S400-S403
40. Hinman AR, Foege WH, de Quadros CA, Patriarca PA, Orenstein WA, Brink EW (1987) The case for global eradication of poliomyelitis. Bull WHO 65:835-840
41. Birmingham ME, Aylward BR, Cochi SL, Hull HF (1977) National immunization days: State of the art. J Infect Dis 175(Suppl.1):S183-S188
42. Benyesh-Melnick M, Melnick JL, Rawls WE, et al. (1967) Studies on the immongenicity, communicability, and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 86:112-136
43. Chen RT, Hausinger S, Dajani AS, et al. (1996) Seroprevalence of antibody against poliovirus in innercity preschool children: implications for vaccination policy in the United States. JAMA 275:1639-1645
44. Ramsey ME, Begg NT, Ghandi J, Brown D (1994) Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 13:1117-1121
45. Richardson G, Linkins RW, Eames MA, Wood DJ, Minor PD, Patriarca PA (1995) Immunogenicity of oral polio vaccine administered in mass campaigns versus routine immunization programs. Bull WHO 73:769-777
46. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines (1997) Combined immunization of infants with oral and inactivated poliovirus vaccines: Results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 175(Suppl.1):S215-S227
47. Reichler MR, Kharabshah S, Rhodes P, Otoum H, BLoch S, Majid MA, et al. (1997) Increased immunogenicity of oral poliovirus vaccine administered in mass vaccination campaigns compared with the routine vaccination program in Jordan. J Infect Dis 175(Suppl.1):S198-S204
48. Deming MS, Linkins RW, Jaiteh KO, Hull HF (1997) The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration. J Infect Dis 175(Suppl.1):S254-S257
49. Posey DL, Linkins RW, Couto Oliveira MJ, Monteiro D, Patriarca PA (1997) The effect of diarrea on oral poliovirus vaccine failure in Brazil. J Infect Dis 175(Suppl.1):S258-S263
50. Terry L (1962) The Association of Cases of Poliomyelitis with the Use of Type 3 Oral Poliomyelitis Vaccines. US Department of Health, Education and Welfare, Washington DC
51. Anonymous (1964) Oral poliomyelitis vaccine. Report of the Special Advisory Committee on Oral Poliomyelitis Vaccines to the Surgeon General of the Public Health Service. JAMA 190:161-163
52. Henderson DA, Witte JJ, Morris L, Langmuir AD (1964) Paralytic disease associated with oral polio vaccines. JAMA 190:41-48
53. Andrus JA, Strebel PM, de Quadros CA, Olive JM (1995) Risk of vaccine-associated paralytic poliomyelitis in the America, 1989-1991. Bull WHO 73:33-40
54. Kohler KA, Banerjee K, Hlady WG, Andrus JK, Sutter RW (2002) Vaccine-associated paralytic poliomyelitis in India, 1999: decreased risk despite massive use of oral polio vaccine. Bull WHO 80:210-216
55. Kohler KA, Banerjee K, Sutter RW (2002) Further clarity on vaccine-associated paralytic polio in India (letter). Bull WHO 80:987
56. Schonberger LB, McGowan JE Jr, Gregg MB (1976) Vaccine-associated poliomyelitis in the United States, 1961-1972. Am J Epidemiol 104:202-211
57. Nkowane BM, Wassilak SGF, Orenstein WA, et al. (1987) Vaccine-associated paralytic poliomyelitis: United States, 1973 through 1984. JAMA 257:1335-1340
58. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States: One decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568-579
59. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, Prevots DR, Strebel PM, Cono J, Wharton M, Orenstein WA, Sutter RW (2004) Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696-1701
60. Sutter RW, Prevots DR (1994) Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 11:426,429-430,435-438
61. de Quadros CA, Andrus JK, Olive J-M, Da Silveira CM, Eikhof RM, Carrasco P, Fitzsimmons JW, Pinheiro FP (1991) Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis J 10:222-229
62. Wright PF, Kim-Farley RJ, de Quadros CA, Robertson SE, Scott RM, Ward NA, Henderson RH (1992) Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 325:1774-1779
63. Olivé J-M, Risi JB Jr, de Quadros CA (1977) National immunization days: Experience in Latin America. J Infect Dis 175(Suppl.1):S189-S193
64. Bilous J, Maher C, Tangermann RH, Aylward RB, et al. (1997) The experience of countries in the Western Pacific Region in conducting national immunization days for polio eradication. J Infect Dis 175(Suppl.1):S194-S197
65. WHO (1996) Expanded Program on Immunization. Field Guide for Supplementary Activities Aimed at Achieving Polio Eradication. World Health Organization, Geneva (WHO document WHO/EPI/GEN/95.01 REV.1)
66. Pan American Health Organization (1985) Director announces campaign to eradicate poliomyelitis from the Americas by 1990. Bull Pan American Health Org 19:213-215
67. CDC (1994) Certification of polio eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep 43:720-722
68. CDC (2001) Certification of polio eradication - Western Pacific Region, 2000. MMWR Morbid Mortal Wkly Rep 50:1-3
69. WHO (2002) Certification of poliomyelitis eradication, European Region, June 2002. Wkly Epidemiol Rec 77:221-223
70. WHO (2004) Progress towards global poliomyelitis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly Epidemiol Rec 79:349-355
71. WHO(2004)Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 79:401-407